Research programme: VEGF gene therapy - Ark Therapeutics

Drug Profile

Research programme: VEGF gene therapy - Ark Therapeutics

Alternative Names: Ad VEGF-D variants; EG013

Latest Information Update: 23 Nov 2012

Price : $50

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Fetal growth retardation

Most Recent Events

  • 08 Nov 2012 Discontinued - Preclinical for Fetal growth retardation in Finland (Intra-arterial)
  • 16 Mar 2011 Preclinical development is ongoing in Finland
  • 30 Nov 2010 Pharmacodynamics data from preclinical studies in Fetal growth retardation released by Ark Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top